Hims & Hers Health ($HIMS) stock declined 2% on Monday after rival GoodRx Holdings ($GDRX) announced a deal with Novo Nordisk ...

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Danish group’s shares rise after it cuts cost for blockbuster diabetes and weight-loss drug for patients without insurance ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Hims & Hers is now projecting that it hit 2025 targets of $1.2 billion of revenue and $100 million of EBITDA one year early, CEO Andrew Dudum told investors during its Q4 and full-year 2023 ...